Influenza Tests Devices Market

Rising prevalence of influenza and the growing geriatric population is driving the market growth

Market CAGR for Influenza Tests Devices is being driven by the rising prevalence of influenza and the growing geriatric population. Epidemic influenza poses a significant public health challenge each season. The World Health Organization (WHO) estimates that influenza has a severe impact on three to five million individuals annually, resulting in 250,000 to 500,000 deaths. Children experience the highest attack rate, while complications such as hospitalization and death are most prevalent in the elderly.

The increasing geriatric population raises the likelihood of a higher incidence of flu. Consequently, the WHO recommends vaccination for individuals aged 65 and above to prevent influenza cases. According to the Centers for Disease Control and Prevention, the U.S. witnessed 9 million flu cases, 4 million influenza-related medical visits, 100,000 flu-related hospitalizations, and 5,000 flu-related deaths during the 2021–2022 season. Similar to previous seasons preceding the COVID-19 outbreak, 83% of fatalities were among older individuals. The weakened immune system of older adults makes them more susceptible to the flu virus.

As a result, it is anticipated that throughout the projection period, demand for the Influenza Tests Devices Market will increase due to the rising prevalence of influenza, and the growing geriatric population. Thus, driving the Influenza Tests Devices Market revenue.

The increasing prevalence of influenza globally is a primary driver for the Global Influenza Tests Devices Market Industry. With millions of cases reported annually, the demand for rapid and accurate testing devices is surging. For instance, the World Health Organization indicates that seasonal influenza epidemics result in approximately 3 to 5 million cases of severe illness each year. This growing incidence necessitates the development and deployment of advanced testing devices, which are crucial for timely diagnosis and treatment. As a result, the market is projected to reach 0.44 USD Billion in 2024, reflecting the urgent need for effective influenza management.

Rising awareness about the importance of influenza testing among healthcare professionals and the general public is driving the Global Influenza Tests Devices Market Industry. Educational campaigns aimed at informing individuals about the symptoms and risks associated with influenza have led to higher testing rates. This heightened awareness encourages timely diagnosis and treatment, ultimately reducing the burden of the disease. Furthermore, healthcare providers are increasingly recognizing the value of rapid testing devices in managing influenza outbreaks. Consequently, the market is poised for growth as more individuals seek testing services, contributing to the overall expansion of the industry.

Government initiatives aimed at combating influenza outbreaks play a crucial role in driving the Global Influenza Tests Devices Market Industry. Various health authorities are investing in research and development to improve testing capabilities and enhance public health responses. For instance, funding programs are being established to support the development of novel testing technologies and to ensure their accessibility in healthcare settings. These initiatives not only foster innovation but also promote the widespread adoption of testing devices. As a result, the market is anticipated to reach 0.92 USD Billion by 2035, reflecting the positive impact of government support on industry growth.

The ongoing focus on global health crises and preparedness strategies significantly influences the Global Influenza Tests Devices Market Industry. Health organizations are prioritizing the development of robust testing infrastructures to mitigate the impact of influenza outbreaks. This proactive approach includes stockpiling testing devices and enhancing laboratory capacities to ensure rapid response capabilities. The emphasis on preparedness not only addresses current health challenges but also anticipates future outbreaks, thereby sustaining demand for testing devices. As the industry evolves, it is likely to see continued investment in testing technologies, ensuring that healthcare systems are equipped to handle influenza effectively.

Technological innovations in influenza testing devices significantly enhance their accuracy and speed, thereby propelling the Global Influenza Tests Devices Market Industry. Recent advancements include the integration of molecular diagnostics and point-of-care testing, which allow for rapid results within minutes. For example, the development of rapid antigen tests has revolutionized the testing landscape, making it easier for healthcare providers to diagnose influenza promptly. These innovations not only improve patient outcomes but also increase the efficiency of healthcare systems. The market is expected to grow at a CAGR of 6.94% from 2025 to 2035, driven by these technological enhancements.

By region, the study provides market insights into North America, Europe, Asia-Pacific, and Rest of the World. The anticipated expansion of the Influenza test devices market in North America can be attributed to several key factors. The rising disease prevalence in the U.S. is anticipated to propel market expansion. According to the Centers for Disease Control and Prevention (CDC), the 2021-2022 influenza season resulted in 9 million illnesses, 4 million medical visits, 10,000 hospitalizations, and 5,000 fatalities. The flu season occurred in two waves, with the second wave experiencing a higher number of hospitalizations.

The expected rise in awareness regarding the significance of flu vaccinations and early detection is also poised to foster market expansion.

Further, the major countries studied in the market report are the US, Canada, Germany, France, the UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.

Figure 2: INFLUENZA TESTS DEVICES MARKET SHARE BY REGION 2022 (USD Billion)

Source: Secondary Research, Primary Research, Market Research Future Database and Analyst Review

Europe's Influenza Tests Devices Market accounts for the second-largest market share as the anticipated high prevalence of influenza is set to be a driving factor for the regional market throughout the forecast period. In the 2022−2023 season, sentinel primary care providers in the EU/EEA tested 81,800 specimens for the influenza virus, with 19,538 (24%) testing positive. This marked a more than four-fold increase in influenza virus detections from sentinel sources compared to the 2021−2022 season and represented the highest number of detections over the past four seasons.

For instance, during the pre-pandemic season of 2019−2020, a total of 11,978 specimens tested positive. Further, the German Influenza Tests Devices Market held the largest market share, and the UK Influenza Tests Devices Market was the fastest-growing market in the European region

The Asia-Pacific Influenza Tests Devices Market is expected to grow at the fastest CAGR from 2023 to 2032. The regional market is poised for rapid growth, driven by increasing awareness and acceptance of influenza diagnostic kits. In 2021, the incidence of influenza virus infections in China declined significantly to approximately 47.4 per 100,000 people from the peak observed in 2019. Notably, the Ministry of Health, Labor, and Welfare released figures for September 11–17, based on reports from 5,000 designated medical institutions, revealing 34,665 influenza cases—an increase of 1.57 times compared to the previous week, averaging 7.03 cases per institution.

Additionally, the growing governmental support for the approval of new diagnostic tests for influenza contributes to the expansion of the influenza diagnostics market in the Asia-Pacific region. Moreover, China’s Influenza Tests Devices Market held the largest market share, and the Indian Influenza Tests Devices Market was the fastest-growing market in the Asia-Pacific region.

Leading market players are investing heavily in research and development to expand their product lines, which will help the Influenza Tests Devices market, grow even more. Market participants are also undertaking a variety of strategic activities to expand their footprint, with important market developments including new product launches, contractual agreements, mergers and acquisitions, higher investments, and collaboration with other organizations. To expand and survive in a more competitive and rising market climate, the Influenza test devices industry must offer cost-effective items.

Manufacturing locally to minimize operational costs is one of the key business tactics used by manufacturers in the Influenza test devices industry to benefit clients and increase the market sector. In recent years, the Influenza test devices industry has offered some of the most significant advantages to the healthcare sector, enabling rapid and accurate diagnosis of influenza infections, leading to timely treatment and effective management of the disease. Major players in the Influenza Tests Devices Market, including Abbott Laboratories, Danaher Corp, Quidelortho Corp, bioMerieux SA, Sekisui Diagnostics LLC, F.

Hoffmann-La Roche Ltd, DiaSorin SpA, Becton Dickinson and Co, Qiagen NV, and Thermo Fisher Scientific Inc are attempting to increase market demand by investing in research and development operations.

Thermo Fisher Scientific Inc (Thermo Fisher) is a provider of medical equipment, analytical instruments, reagents, and consumables, as well as software and services addressing complex analytical challenges in research, diagnostics, and clinical laboratories. The company offers solutions in cellular analysis, biology, flow cytometry, and synthetic biology, with a product range covering mass spectrometry, genetic sequencing, electron microscopy, protein, and molecular biology research. Thermo Fisher serves diverse sectors including pharmaceutical and biotech companies, academic and research institutions, clinical diagnostic labs, and government agencies, along with the environmental, industrial quality, and process control sectors.

Its distribution channels include direct sales, e-commerce, and third-party distributors across the Americas, Asia-Pacific, and Europe. Headquartered in Waltham, Massachusetts, USA, Thermo Fisher Scientific acquired Mesa Biotech, a leading developer and manufacturer of next-generation molecular diagnostic tests, in January 2021 for USD 450 million. This strategic acquisition enhances Thermo Fisher Scientific's test portfolio by incorporating Mesa's PCR-based Accula rapid point-of-care test platform for SARS-CoV-2, RSV, Influenza A and B, and Strep A

Becton Dickinson and Co. (BD) is a medical technology company specializing in the manufacturing and sale of medical devices, reagents, and instruments. Its diverse product portfolio includes syringes, pen needles, intravenous catheters, infusion pumps, automated medication dispensing systems, respiratory ventilation equipment, diagnostic tools, and more. BD caters to various sectors, including life science researchers, healthcare institutions, clinical laboratories, the pharmaceutical industry, and the general public. The company operates globally, with a presence in the Americas, Europe, the Middle East, Africa, and Asia-Pacific. Headquartered in New Jersey, USA, BD recently received emergency use authorization from the U.S.

Food and Drug Administration in February 2023 for a novel molecular diagnostic combo test targeting influenza A + B, aiming to address diseases during the current and upcoming respiratory virus seasons.